Company Overview
Snapshot
Founded in May 2022, Elio Labs operates with 11–50 employees. The company has secured funding across one disclosed round from 1 investor, with UpWest participating in its Seed round in December 2024.
Business overview
Elio Labs develops an AI-powered optical imaging platform designed to analyze biological samples with high resolution and in real time. Its core technology integrates computational analysis with microscopy-based sensing, enabling researchers to extract dynamic biological insights from cells and tissues. The company serves markets within drug discovery, disease research, and experimental biology, operating primarily within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology.
Log in to access full profile ›Company Intelligence Q&A
- When was Elio Labs founded?
- Elio Labs was founded in May 2022.
- What is Elio Labs' primary sector?
- Elio Labs' primary sector is Health Tech & Life Sciences, with a focus on Pharma & Medical Biotechnology.
- How many employees does Elio Labs have?
- Elio Labs has 11–50 employees.
- What does Elio Labs' technology do?
- Elio Labs develops a technology platform that combines advanced optical imaging and artificial intelligence to analyze biological samples at high resolution and in real time, supporting applications such as drug discovery and disease research.